A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Centrexion Therapeutics
  • Most Recent Events

    • 30 Oct 2017 According to a Centrexion Therapeutics media release, 12-week data from this trial will be presented at the American College of Rheumatology and the Association of Rheumatology Health Professionals' (ACR/ARHP) 2017 Annual Meeting.
    • 20 Jul 2017 Results from this trial will be presented at the American Podiatric Medical Association's (APMA) 2017 Annual Scientific Meeting.
    • 20 May 2017 Primary endpoint (Change from Baseline in average neuroma foot pain (Diary) with walking using the NPRS) has not been met,according to the results published at the 36th Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top